Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies.[1] He is a co-founder of Juno Therapeutics.[2][3][4]
Philip Greenberg | |
|---|---|
| Nationality | American |
| Education | |
| Known for | T cell receptor T cell therapy |
| Scientific career | |
| Fields | Hematology |
| Institutions | |
| Website | Fred Hutch page |
Education and research
editGreenberg graduated from Washington University in St. Louis with a degree in biology; he received his M.D. in 1971 from SUNY Downstate Medical Center. After completing postdoctoral training at the University of California at San Diego, he joined the Fred Hutchinson Cancer Center and the Division of Oncology at the University of Washington, in 1976.[5] His research is focused on T cell adoptive immunotherapy. His group has demonstrated the potential of isolating antigen-specific T cells and growing them to perform in vivo activity against a disease.[6][7][8] He has also done work on re-engineering T cells to produce TCR-T that will work for non-leukemia malignancies.[9]
Awards and honors
editThis section of a biography of a living person needs additional citations for verification. (October 2023) |
- 1978–1981 American Cancer Society Junior Clinical Faculty Fellowship[10]
- 1987 elected member, American Society for Clinical Investigation[10]
- 1991–1998; 1998–2007 National Institutes of Health MERIT Award(s)[10]
- 1998 elected member, Association of American Physicians[10]
- 2007 elected Fellow, American Association for the Advancement of Science[10]
- 2008 elected Fellow, American College of Physicians[10]
- 2011 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, Cancer Research Institute[11]
- 2015–present editor-in-chief, Cancer Immunology Research, AACR[12]
- 2016–present selected as investigator of the Parker Institute for Cancer Immunotherapy[13]
- 2017–2020 elected to board of directors, AACR[14]
- 2018 awarded SITC’s highest honor, the Richard V. Smalley, M.D., Memorial Award and Lectureship[15]
- 2018 Gold Award for Achievement in Medical Research, Seattle Business Magazine [10]
- 2019 E. Donnall Thomas Lecture and Prize, American Society of Hematology[6]
- 2019 elected a Fellow of the AACR Academy[10]
- 2019 elected a Distinguished Fellow of the American Association of Immunologists[16]
- 2020 Precision Medicine World Conference Luminary Award[17]
- 2021 elected Society for Immunotherapy of Cancer Inaugural Class of Fellows of the Academy of Immuno-Oncology[18]
- 2023 elected president of the AACR for 2023–2024[19]
- 2023 elected member of the National Academy of Sciences[20]
References
edit- ^ "Dr. Phil Greenberg named 2018 Leader in Health Care". Fred Hutch. March 2, 2018.
- ^ "A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies". STAT. January 13, 2022.
- ^ "Leading cancer research centers team up to launch biotech startup focused on cancer immunotherapy". Fierce Biotech. December 4, 2013.
- ^ Schubert, Charlotte (March 30, 2022). "Biotech vet Phil Greenberg on his new cancer-fighting startup and immunotherapy's next phase". GeekWire.
- ^ "Philip – Greenberg – PMWC Precision Medicine World Conference". pmwcintl.com. Retrieved July 19, 2022.
- ^ a b "Philip Greenberg, MD, to Present the 2019 American Society of Hematology E. Donnall Thomas Lecture". www.hematology.org.
- ^ Riddell, Stanley R.; Watanabe, Kathe S.; Goodrich, James M.; Li, Cheng R.; Agha, Mounzer E.; Greenberg, Philip D. (July 10, 1992). "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones". Science. 257 (5067): 238–241. Bibcode:1992Sci...257..238R. doi:10.1126/science.1352912. PMID 1352912.
- ^ Walter, Elizabeth A.; Greenberg, Philip D.; Gilbert, Mark J.; Finch, Rosalynde J.; Watanabe, Käthe S.; Thomas, E. Donnall; Riddell, Stanley R. (October 19, 1995). "Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor". New England Journal of Medicine. 333 (16): 1038–1044. doi:10.1056/NEJM199510193331603. PMID 7675046.
- ^ "Spotlight on Phil Greenberg". Fred Hutch.
- ^ a b c d e f g h "Philip D. Greenberg, MD". American Association for Cancer Research. Retrieved December 21, 2023.
- ^ "Greenberg receives immunotherapy award". fredhutch.org. September 26, 2011.
- ^ "Good News at Fred Hutch". fredhutch.org. October 1, 2015.
- ^ "Good News: Fred Hutch immunotherapy expert Dr. Phil Greenberg joins Parker Institute". November 30, 2017.
- ^ "Dr. Philip Greenberg elected to serve on AACR board of directors". fredhutch.org. March 31, 2017.
- ^ "Philip D. Greenberg, MD | SITC 2018 Keynote Speaker". sitcancer.org. Retrieved July 19, 2022.
- ^ "Dr. Philip Greenberg elected a Distinguished Fellow of the American Association of Immunologists". fredhutch.org. April 19, 2019. Retrieved February 27, 2022.
- ^ "Philip D. Greenberg, MD, FAACR, Elected as American Association for Cancer Research President-Elect for 2022–2023". American Association for Cancer Research. Retrieved December 21, 2023.
- ^ "Society for Immunotherapy of Cancer (SITC) Announces Inaugural Class of Fellows to the Academy of Immuno-Oncology". www.sitcancer.org. Retrieved December 21, 2023.
- ^ "American Association for Cancer Research Inaugurates New Leadership at the AACR Annual Business Meeting of Members 2023". Retrieved May 17, 2023.
- ^ Fronek, Laurie (May 11, 2023). "Dr. Philip Greenberg elected to National Academy of Sciences".
External links
edit- Philip Greenberg publications indexed by Google Scholar
   | This biographical article related to medicine in the United States is a stub. You can help Wikipedia by expanding it. |